Ab Studio’s Post

Unlocking the future of drug discovery! Harness the power of our in-house Cryo-EM at XralPi to revolutionize how you gather insights on target structures and facilitate drug discovery. Dive deeper into our capabilities by clicking the link below!

Thoughts on this? >> Alterome raises $132M to take next generation of AKT, KRAS inhibitors into clinic >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharmaceutical #healthcare #pharma

Dr. Kathleen Metters, Chair of Syntara, will address shareholders today at the 2024 Annual General Meeting, reflecting on a transformative year for the company. Key achievements include completing the shift from Pharmaxis to a streamlined, purpose-driven Syntara, reducing annual expenses by $14 million, and advancing the phase 2 trial of SNT-5505, now fully recruited for myelofibrosis. Additionally, Syntara secured non-dilutive funding for two new studies in myelodysplastic syndrome, set to begin in 2025. Looking ahead, Syntara will present interim data at ASH and engage with the FDA to guide pivotal trial design, reaffirming their focus on advancing SNT-5505 as a potentially transformative therapy. #Syntara #AGM2024 #Biotech #Myelofibrosis #ClinicalTrials #SNT5505

Thoughts on this? >> Alterome raises $132M to take next generation of AKT, KRAS inhibitors into clinic >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #productmarketing #healthcare #biotech

Read our new tech note on TL1A:DR3 - A Pathway for Immunomodulation! Learn more about the mechanisms underlying TL1A:DR3 signaling, its physiological roles, and its potential applications in clinical settings. Find novel enabling tools for your TL1A-DR3 drug discovery and contact us today! #TL1A #immunotherapy #drugdiscovery https://hubs.ly/Q02zvNfl0

Gene&Cell Therapy >> Gamida to go private; Stoke aims to raise $75M: Plus, news about a TUDCA study, PDS Biotechnology and Allarity Therapeutics: Gamida Cell to go private: The commercial-stage cell therapy biotech will no longer trade on the Nasdaq after Highbridge Capital Management, its principal lender, restructures the company. The penny stock $GMDA was down 84% in Wednesday trading. Gamida secured FDA approval for its cell therapy Omisirge in April. Then, in January, it said it was “actively pursuing” alternative routes to keep going. — Kyle LaHucik Stoke eyes $75M offering: The Boston-area biotech plans to sell about $75 million worth of shares after its stock price popped in response to clinical data on a genetic epilepsy treatment candidate. — Kyle LaHucik TUDCA study reports Ph3 fail for experimental ALS supplement: The study, which was conducted by a consortium of European hospitals, did not show a difference between the supplement tauroursodeoxycholic acid, or TUDCA, and placebo on a primary endpoint that measures patient function (ALSFRS-R). It also did not meet any secondary endpoints like survival or changes in biomarkers. Investors were closely watching the study ahead of Amylyx’s Phase 3 readout, which came in negative earlier this month. Amylyx’s drug Relyvrio is made up of a higher concentration of taurursodiol, the active chemical in TUDCA. — Max Gelman PDS Biotechnology’s stock drops after it changed pivotal study plan: The biotech is no longer pursuing a Phase 3 study of its experimental drug PDS01ADC in combination with Merck’s Keytruda in HPV-positive head and neck cancer. It’s instead discussing a triple combination pivotal trial of PDS01ADC, Keytruda and a T cell activating immunotherapy that the company hopes to start later this year. PDS shares $PDSB were down 12% on Wednesday morning. — Lei Lei Wu Allarity Therapeutics pivots: The penny stock biotech is stopping work on its tyrosine kinase inhibitor dovitinib and the chemotherapy Ixempra, citing the need to cut costs. It is instead focusing on advancing stenoparib, a PARP and Tankyrase inhibitor currently in a Phase 2 monotherapy trial in advanced ovarian cancer. — Lei Lei Wu #lucidquest #genetherapy #celltherapy

Don't miss it! Next week you can follow our SCREEN-seq webinar LIVE! In the webinar we explain what SCREEN-seq is and how it can accelerate drug discovery screening projects by adding high throughput bulk sequencing to your research. Register through the link in our post below!

I love this explainer of how RNA drugs work. It's ridiculously simple. #omicsnews #precisionmedicine #RNA #bitoechnews #pharmanews #proteomics #biomarkers #healthcareinnovation

#Sirolimus leads to greater improvement in endothelial function in the target vessel compared to Paclitaxel after 6 months as per the Limus Flow randomized clinical trial update presented at LINC 2024. Check out this interview from Prof. Dr. Christos Rammos, MHBA highlighting the latest data of his study and the SELUTION SLR™ Drug Eluting Balloon uniqueness, which may be of benefit to most complex patients with PAD #PeripheralInterventions #PAD #CLTI #DCB #DEB #SELUTIONSLR

Check out this presentation to hear how Totus Medicines collaborated with the LuminexPLORE Lab to convert assays originally performed by western blot to a dual-reporter xMAP® assay for the xMAP INTELLIFLEX® DR-SE System that would measure the percentage of PI3Kα that bound to the candidate drug. Watch now: https://hubs.li/Q02Vf6Md0 Discover new possibilities in multiplexing with the xMAP INTELLIFLEX DR-SE System: https://hubs.li/Q02Vfcv-0 #xMAP #INTELLIFLEX